Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이진화 | * |
dc.date.accessioned | 2016-08-28T10:08:16Z | - |
dc.date.available | 2016-08-28T10:08:16Z | - |
dc.date.issued | 2013 | * |
dc.identifier.issn | 1027-3719 | * |
dc.identifier.other | OAK-9630 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/223326 | - |
dc.description.abstract | SETTING: Multicentre study. OBJECTIVE: To define the clinical characteristics of patients with tuberculosis (TB) destroyed lung due to past TB. DESIGN: We reviewed patients with TB-destroyed lung between May 2005 and June 2011. RESULTS: A total of 595 patients from 21 hospitals were enrolled. The mean age was 65.63 ± 0.47 (mean ± standard error); 60.5% were male. The mean number of lobes involved was 2.59 ± 0.05. Pleural thickening was observed in 54.1% of the patients. Mean forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC, bronchodilator response and number of exacerbations per year were respectively 2.06 ± 0.03 l (61.26% ± 0.79), 1.16 ± 0.02 l (49.05% ± 0.84), 58.03% ± 0.70, 5.70% ± 0.34, and 0.40 ± 0.04. The number of lobes involved was significantly correlated with FVC and FEV1, and with the number of exacerbations per year. Use of long-acting muscarinic antagonists or long-acting beta-2 agonists plus inhaled corticosteroids resulted in bronchodilatory effects. Multivariable regression analysis showed that age, initial FEV1 (%) and number of exacerbations during follow-up were independent factors affecting change in FEV1. CONCLUSION: Decreased lung function with exacerbation, and progressive decline of FEV1 were observed in patients with TB-destroyed lung. © 2013 The Union. | * |
dc.language | English | * |
dc.title | Clinical characteristics of patients with tuberculosis-destroyed lung | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 17 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 67 | * |
dc.relation.lastpage | 75+i | * |
dc.relation.journaltitle | International Journal of Tuberculosis and Lung Disease | * |
dc.identifier.doi | 10.5588/ijtld.12.0351 | * |
dc.identifier.wosid | WOS:000313227600013 | * |
dc.identifier.scopusid | 2-s2.0-84871255203 | * |
dc.author.google | Rhee C.K. | * |
dc.author.google | Yoo K.H. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Park M.J. | * |
dc.author.google | Kim W.J. | * |
dc.author.google | Park Y.B. | * |
dc.author.google | Hwang Y.I. | * |
dc.author.google | Kim Y.S. | * |
dc.author.google | Jung J.Y. | * |
dc.author.google | Moon J.Y. | * |
dc.author.google | Rhee Y.K. | * |
dc.author.google | Park H.K. | * |
dc.author.google | Lim J.H. | * |
dc.author.google | Park H.Y. | * |
dc.author.google | Lee S.W. | * |
dc.author.google | Kim Y.H. | * |
dc.author.google | Lee S.H. | * |
dc.author.google | Yoon H.K. | * |
dc.author.google | Kim J.W. | * |
dc.author.google | Kim J.S. | * |
dc.author.google | Kim Y.K. | * |
dc.author.google | Oh Y.M. | * |
dc.author.google | Lee S.D. | * |
dc.author.google | Kim H.J. | * |
dc.contributor.scopusid | 이진화(56646645800;58376333800) | * |
dc.date.modifydate | 20240419140935 | * |